INFLAMMA Trademark

Trademark Overview

On Monday, October 8, 2018, a trademark application was filed for INFLAMMA with the United States Patent and Trademark Office. The USPTO has given the INFLAMMA trademark a serial number of 88147249. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 24, 2024. This trademark is owned by Inflamma Therapeutics, LLC. The INFLAMMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

biotechnology research; research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines; medical and scientific research, discovery, development and design of pharmaceutical and therapeutic preparations; discovery, development and design of pharmaceutical and therapeutic preparations for the treatment of diseases and disorders through modulation of the immune response
inflamma

General Information

Serial Number88147249
Word MarkINFLAMMA
Filing DateMonday, October 8, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 26, 2021

Trademark Statements

Pseudo MarkINFLAMMATION
Goods and Servicesbiotechnology research; research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines; medical and scientific research, discovery, development and design of pharmaceutical and therapeutic preparations; discovery, development and design of pharmaceutical and therapeutic preparations for the treatment of diseases and disorders through modulation of the immune response

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, October 18, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameInflamma Therapeutics, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressSan Diego, CA 92103
Party NameInflamma Therapeutics, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSan Diego, CA 92103

Trademark Events

Event DateEvent Description
Thursday, January 17, 2019SUSPENSION LETTER WRITTEN
Thursday, October 11, 2018NEW APPLICATION ENTERED
Thursday, October 18, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 17, 2019ASSIGNED TO EXAMINER
Thursday, January 17, 2019LETTER OF SUSPENSION E-MAILED
Thursday, January 17, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, April 8, 2019ASSIGNED TO EXAMINER
Thursday, August 8, 2019SUSPENSION LETTER WRITTEN
Thursday, August 8, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, August 8, 2019LETTER OF SUSPENSION E-MAILED
Tuesday, February 18, 2020ASSIGNED TO LIE
Tuesday, February 18, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, February 18, 2020DATA MODIFICATION COMPLETED
Wednesday, September 16, 2020SUSPENSION LETTER WRITTEN
Wednesday, September 16, 2020LETTER OF SUSPENSION E-MAILED
Wednesday, September 16, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, November 2, 2020NON-FINAL ACTION E-MAILED
Monday, November 2, 2020NON-FINAL ACTION WRITTEN
Monday, November 2, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 23, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 2, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 2, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 17, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 6, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 26, 2021PUBLISHED FOR OPPOSITION
Tuesday, February 23, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, January 26, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, April 7, 2021EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, May 18, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 18, 2021SOU TEAS EXTENSION RECEIVED
Thursday, November 18, 2021SOU EXTENSION 1 FILED
Friday, May 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 18, 2022SOU EXTENSION 3 GRANTED
Thursday, November 18, 2021SOU EXTENSION 1 GRANTED
Saturday, November 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 18, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, May 18, 2022SOU EXTENSION 2 FILED
Wednesday, May 18, 2022SOU EXTENSION 2 GRANTED
Friday, November 18, 2022SOU TEAS EXTENSION RECEIVED
Friday, November 18, 2022SOU EXTENSION 3 FILED
Tuesday, November 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, May 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, November 18, 2023SOU EXTENSION 5 FILED
Wednesday, November 29, 2023SOU EXTENSION 5 GRANTED
Thursday, November 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 18, 2023SOU TEAS EXTENSION RECEIVED
Thursday, May 18, 2023SOU EXTENSION 4 FILED
Thursday, May 18, 2023SOU EXTENSION 4 GRANTED
Saturday, November 18, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 29, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 24, 2024ABANDONMENT - NO USE STATEMENT FILED

Related Keywords

inflamma development pharmaceutical preparations research design therapeutic biotechnology discovery through modulation